FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897896107> ?p ?o ?g. }

• W2897896107 endingPage "e183485" @default.
• W2897896107 startingPage "e183485" @default.
• W2897896107 abstract "<h3>Importance</h3> Cannabinoids have antispastic and analgesic effects; however, their role in the treatment of multiple sclerosis (MS) symptoms is not well defined. <h3>Objective</h3> To conduct a systematic review and meta-analysis to assess the efficacy and tolerability of medicinal cannabinoids compared with placebo in the symptomatic treatment of patients with MS. <h3>Data Sources</h3> MEDLINE and the Cochrane Library Plus up to July 26, 2016. No restrictions were applied. The search was completed with information from ClinicalTrials.gov. <h3>Study Selection</h3> Randomized, double-blind, and placebo-controlled trials evaluating the effect of medicinal cannabinoids by oral or oromucosal route of administration on the symptoms of spasticity, pain, or bladder dysfunction in adult patients with MS. <h3>Data Extraction and Synthesis</h3> The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed. Effect sizes were calculated as standardized mean difference (SMD) for efficacy, and rate ratio (RR) for tolerability. Within each study, those SMDs evaluating the same outcome were combined before the meta-analysis to obtain a single value per outcome and study. Pooling of the studies was performed on an intention-to-treat basis by means of random-effect meta-analysis. <h3>Main Outcomes and Measures</h3> Spasticity (on the Ashworth and Modified Ashworth scales and subjective), pain, bladder dysfunction, adverse events, and withdrawals due to adverse events. <h3>Results</h3> Seventeen selected trials including 3161 patients were analyzed. Significant findings for the efficacy of cannabinoids vs placebo were SMD = −0.25 SD (95% CI, −0.38 to −0.13 SD) for spasticity (subjective patient assessment data), −0.17 SD (95% CI, −0.31 to −0.03 SD) for pain, and −0.11 SD (95% CI, −0.22 to −0.0008 SD) for bladder dysfunction. Results favored cannabinoids. Findings for tolerability were RR = 1.72 patient-years (95% CI, 1.46-2.02 patient-years) in the total adverse events analysis and 2.95 patient-years (95% CI, 2.14-4.07 patient-years) in withdrawals due to adverse events. Results described a higher risk for cannabinoids. The serious adverse events meta-analysis showed no statistical significance. <h3>Conclusions and Relevance</h3> The results suggest a limited efficacy of cannabinoids for the treatment of spasticity, pain, and bladder dysfunction in patients with MS. Therapy using these drugs can be considered as safe. <h3>Trial Registration</h3> PROSPERO Identifier:CRD42014015391" @default.
• W2897896107 created "2018-10-26" @default.
• W2897896107 creator A5033539160 @default.
• W2897896107 creator A5036831245 @default.
• W2897896107 creator A5058384218 @default.
• W2897896107 creator A5069131824 @default.
• W2897896107 date "2018-10-12" @default.
• W2897896107 modified "2023-10-01" @default.
• W2897896107 title "Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis" @default.
• W2897896107 cites W1181448258 @default.
• W2897896107 cites W1512895399 @default.
• W2897896107 cites W1705148237 @default.
• W2897896107 cites W1790460690 @default.
• W2897896107 cites W1801725150 @default.
• W2897896107 cites W1974654819 @default.
• W2897896107 cites W1976848876 @default.
• W2897896107 cites W1980502203 @default.
• W2897896107 cites W1984052269 @default.
• W2897896107 cites W1984516218 @default.
• W2897896107 cites W1987613482 @default.
• W2897896107 cites W1988039811 @default.
• W2897896107 cites W2036272035 @default.
• W2897896107 cites W2043053000 @default.
• W2897896107 cites W2056588555 @default.
• W2897896107 cites W206987770 @default.
• W2897896107 cites W2075298115 @default.
• W2897896107 cites W2076029586 @default.
• W2897896107 cites W2087232473 @default.
• W2897896107 cites W2095413919 @default.
• W2897896107 cites W2105601238 @default.
• W2897896107 cites W2108961889 @default.
• W2897896107 cites W2110094427 @default.
• W2897896107 cites W2110690684 @default.
• W2897896107 cites W2112303081 @default.
• W2897896107 cites W2114826780 @default.
• W2897896107 cites W2120227293 @default.
• W2897896107 cites W2130235475 @default.
• W2897896107 cites W2137070227 @default.
• W2897896107 cites W2140180096 @default.
• W2897896107 cites W2146626244 @default.
• W2897896107 cites W2156098321 @default.
• W2897896107 cites W2171321375 @default.
• W2897896107 cites W2207407866 @default.
• W2897896107 cites W2233327055 @default.
• W2897896107 cites W2280334572 @default.
• W2897896107 cites W246286872 @default.
• W2897896107 cites W2555514711 @default.
• W2897896107 cites W2569092898 @default.
• W2897896107 cites W2603679665 @default.
• W2897896107 cites W2746272542 @default.
• W2897896107 cites W4231243400 @default.
• W2897896107 cites W4234649800 @default.
• W2897896107 cites W4235513883 @default.
• W2897896107 cites W4236759789 @default.
• W2897896107 cites W4244946931 @default.
• W2897896107 cites W4246028900 @default.
• W2897896107 cites W4247251110 @default.
• W2897896107 cites W4249999102 @default.
• W2897896107 cites W4251083287 @default.
• W2897896107 cites W4253862884 @default.
• W2897896107 cites W4294215472 @default.
• W2897896107 cites W4297918764 @default.
• W2897896107 doi "https://doi.org/10.1001/jamanetworkopen.2018.3485" @default.
• W2897896107 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324456" @default.
• W2897896107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646241" @default.
• W2897896107 hasPublicationYear "2018" @default.
• W2897896107 type Work @default.
• W2897896107 sameAs 2897896107 @default.
• W2897896107 citedByCount "52" @default.
• W2897896107 countsByYear W28978961072018 @default.
• W2897896107 countsByYear W28978961072019 @default.
• W2897896107 countsByYear W28978961072020 @default.
• W2897896107 countsByYear W28978961072021 @default.
• W2897896107 countsByYear W28978961072022 @default.
• W2897896107 countsByYear W28978961072023 @default.
• W2897896107 crossrefType "journal-article" @default.
• W2897896107 hasAuthorship W2897896107A5033539160 @default.
• W2897896107 hasAuthorship W2897896107A5036831245 @default.
• W2897896107 hasAuthorship W2897896107A5058384218 @default.
• W2897896107 hasAuthorship W2897896107A5069131824 @default.
• W2897896107 hasBestOaLocation W28978961071 @default.
• W2897896107 hasConcept C126322002 @default.
• W2897896107 hasConcept C142724271 @default.
• W2897896107 hasConcept C168563851 @default.
• W2897896107 hasConcept C197934379 @default.
• W2897896107 hasConcept C204787440 @default.
• W2897896107 hasConcept C27081682 @default.
• W2897896107 hasConcept C2776478404 @default.
• W2897896107 hasConcept C2778375690 @default.
• W2897896107 hasConcept C2779012798 @default.
• W2897896107 hasConcept C42219234 @default.
• W2897896107 hasConcept C71924100 @default.
• W2897896107 hasConcept C95190672 @default.
• W2897896107 hasConceptScore W2897896107C126322002 @default.
• W2897896107 hasConceptScore W2897896107C142724271 @default.
• W2897896107 hasConceptScore W2897896107C168563851 @default.
• W2897896107 hasConceptScore W2897896107C197934379 @default.
• W2897896107 hasConceptScore W2897896107C204787440 @default.

• next